{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:18:52Z","timestamp":1782429532220,"version":"3.54.5"},"reference-count":30,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2024,10,2]]},"DOI":"10.1080\/03007995.2024.2391553","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:34:55Z","timestamp":1725377695000},"page":"1769-1783","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1080","volume":"40","author":[{"given":"Donna","family":"Reece","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-9120","authenticated-orcid":false,"given":"Joris","family":"Diels","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Van Sanden","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica NV, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ammann","sequence":"additional","affiliation":[{"name":"Janssen Global Services, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heuck","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Kane","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Titusville, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Peterson","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Horsham, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30081-8"},{"key":"e_1_3_6_9_1","unstructured":"TALVEY (talquetamab-tgvs). Prescribing information. Horsham (PA): Janssen Biotech Inc; 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf"},{"key":"e_1_3_6_10_1","unstructured":"TALVEY. Summary of product characteristics. Leiden (The Netherlands): Janssen Biologics B.V.; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"e_1_3_6_13_1","unstructured":"Schinke CD Touzeau C Minnema MC et\u00a0al. editors. Pivotal phase 2 MonumenTAL-1 results of talquetamab a GPRC5D\u2009\u00d7\u2009CD3 bispecific antibody for relapsed\/refractory multiple myeloma. The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; 2023 Jun 2\u20136. Chicago IL USA & Virtual."},{"key":"e_1_3_6_14_1","unstructured":"BLENREP (belantamab mafodotin-blmf). Prescribing information. Research Triangle Park (NC): GlaxoSmithKline; 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf"},{"key":"e_1_3_6_15_1","unstructured":"BLENREP. Summary of product characteristics. San Polo di Torrile (Italy): GlaxoSmithKline Manufacturing SpA; 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blenrep-epar-product-information_en.pdf"},{"key":"e_1_3_6_16_1","unstructured":"XPOVIO (selinexor). Prescribing information. Newton (MA): Karyopharm Therapeutics Inc; 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212306s000lbl.pdf"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_6_18_1","unstructured":"Myeloma Patients Europe. Selinexor receives positive opinion from the EMA for the treatment of refractory myeloma: Myeloma Patients Europe; 2021. Available from: https:\/\/www.mpeurope.org\/2021\/01\/30\/selinexor-receives-positive-opinion-from-the-ema-for-refractory-myeloma\/"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34987"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1003"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2218543"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.709"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462319000333"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913143"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2024.2391553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:24:54Z","timestamp":1728487494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2024.2391553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,2]]}},"alternative-id":["10.1080\/03007995.2024.2391553"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2024.2391553","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}